Eli Lilly and Co (NYSE:LLY) – Investment analysts at SunTrust Banks raised their FY2018 earnings estimates for shares of Eli Lilly and in a report released on Thursday. SunTrust Banks analyst J. Boris now anticipates that the company will earn $4.91 per share for the year, up from their prior forecast of $4.82. SunTrust Banks also issued estimates for Eli Lilly and’s FY2019 earnings at $5.41 EPS, FY2020 earnings at $6.16 EPS and FY2022 earnings at $7.39 EPS.
LLY has been the topic of a number of other research reports. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price target on the stock in a research note on Thursday, October 26th. Morgan Stanley raised their price target on Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 21st. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the stock a “sell” rating in a research note on Wednesday, November 1st. Berenberg Bank restated a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research note on Thursday, October 26th. Finally, Goldman Sachs Group downgraded Eli Lilly and from a “buy” rating to a “neutral” rating and raised their price target for the stock from $86.98 to $95.00 in a research note on Tuesday, January 16th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. Eli Lilly and presently has a consensus rating of “Hold” and a consensus target price of $92.02.
Eli Lilly and (LLY) traded up $0.79 during trading hours on Monday, reaching $76.44. The company had a trading volume of 1,937,195 shares, compared to its average volume of 5,310,823. The stock has a market cap of $83,870.00, a P/E ratio of -382.20, a PEG ratio of 1.42 and a beta of 0.23. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and has a 12-month low of $73.69 and a 12-month high of $89.09.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. The firm had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $5.93 billion. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.95 EPS.
Several institutional investors and hedge funds have recently bought and sold shares of LLY. Beach Investment Management LLC. acquired a new stake in shares of Eli Lilly and in the 2nd quarter valued at approximately $400,000. Jennison Associates LLC raised its holdings in Eli Lilly and by 13.9% during the second quarter. Jennison Associates LLC now owns 1,947,061 shares of the company’s stock worth $160,243,000 after purchasing an additional 237,342 shares during the last quarter. Investment Management of Virginia LLC raised its holdings in Eli Lilly and by 1.0% during the second quarter. Investment Management of Virginia LLC now owns 11,645 shares of the company’s stock worth $958,000 after purchasing an additional 110 shares during the last quarter. Marshall Wace North America L.P. raised its holdings in Eli Lilly and by 571.7% during the second quarter. Marshall Wace North America L.P. now owns 387,014 shares of the company’s stock worth $31,735,000 after purchasing an additional 329,393 shares during the last quarter. Finally, Boston Family Office LLC raised its holdings in Eli Lilly and by 0.9% during the second quarter. Boston Family Office LLC now owns 10,580 shares of the company’s stock worth $871,000 after purchasing an additional 90 shares during the last quarter. 76.20% of the stock is owned by institutional investors and hedge funds.
In other news, insider Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.09, for a total value of $72,981.00. Following the completion of the sale, the insider now directly owns 4,130 shares of the company’s stock, valued at approximately $334,901.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the completion of the sale, the senior vice president now directly owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The disclosure for this sale can be found here. Insiders sold a total of 259,610 shares of company stock worth $22,727,406 over the last quarter. Company insiders own 0.20% of the company’s stock.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a dividend yield of 2.94%. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is -1,040.00%.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/14/equities-analysts-set-expectations-for-eli-lilly-and-cos-fy2018-earnings-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.